Erectile dysfunction (ED) is a worldwide commonly reported condition; epidemiological data showed a prevalence ranging from 2.3 to 53.4% within different population subsets. In this context, the advent of phosphodiesterase type 5 inhibitors (PDE5is) in the second mid of 1990s has deeply changed the treatment scenario of this bothersome condition. Being user-friendly compounds with an excellent overall safety profile, PDE5is emerged as the first-line treatment for ED, thus overcoming topical alprostadil and intracavernous injections (ICIs). However, available data on treatment-utilization patterns and medical prescriptions of PDE5is showed a range of as wide as 22-78% of patients reporting to purchase PDE5is even without a proper medical prescription. Moreover, an increase in the recreational use of PDE5is among young men has been observed in the last decades, with a worrisome diffusion of potential health-risky behaviours associated with this habit. Indeed, treatment of ED should carefully follow internationally based clinical guidelines to avoid inappropriate drug prescriptions, which may eventually expose treated patients to drug-related side effects. Thereof, a careful assessment of the so-called modifiable and reversible ED risk factors along with a patient-tailored screening for potential contraindications to the treatment itself should be performed in every case. Lastly, although conclusive data still lack, the potential association between life-risky PDE5is side effects (i.e. cardiovascular adverse events, melanoma skin cancer and worsening of prostate cancer outcomes) should be carefully taken into account when counselling patients for ED treatment.
Urologia 2017; 84(3): 121 - 129
Article Type: REVIEW
AuthorsPaolo Capogrosso, Eugenio Ventimiglia, Davide Oreggia, Andrea Salonia, Francesco Montorsi
- • Accepted on 22/05/2017
- • Available online on 05/07/2017
- • Published in print on 01/08/2017
This article is available as full text PDF.
- Capogrosso, Paolo [PubMed] [Google Scholar] 1, 2, * Corresponding Author (firstname.lastname@example.org)
- Ventimiglia, Eugenio [PubMed] [Google Scholar] 1, 2
- Oreggia, Davide [PubMed] [Google Scholar] 1, 2
- Salonia, Andrea [PubMed] [Google Scholar] 1, 2
- Montorsi, Francesco [PubMed] [Google Scholar] 1, 2
Università Vita-Salute San Raffaele, Milan - Italy
Division of Experimental Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan - Italy